by Internet Medical Society
Radicava is one of the two treatments approved by the U.S. FDA for treating Amyotrophic Lateral Sclerosis. It is the first therapy for ALS in over twenty years, and was approved (by FDA) in May 2017. The radicava cost may vary and depends on certain factors. In Radicava, the key active ingredient is edaravone, which has a neuroprotective effect, and in certain patients declines the progression of Amyotrophic Lateral Sclerosis by eliminating free-radicals from the system. It is given to patients in 60 mg doses, which are administered with an intravenous infusion. It takes around 60 minutes to complete a treatment infusion session.